3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Colorectal Neoplasms
38
Stomach Neoplasms
24
Rectal Neoplasms
19
Pancreatic Neoplasms
17
Lymphoma, Large B-Cell, Diffuse
14
Colonic Neoplasms
14
Esophageal Neoplasms
12
Adenocarcinoma Of Esophagus
12
Carcinoma, Non-Small-Cell Lung
10
Neoplasms
9
Neoplasm Metastasis
9
Adenocarcinoma
9
Cholangiocarcinoma
8
Biliary Tract Neoplasms
6
Ovarian Neoplasms
5
Parkinson Disease 4, Autosomal Dominant Lewy Body
4
Esophageal Squamous Cell Carcinoma
4
Carcinoma, Hepatocellular
4
Lymphoma, Non-Hodgkin
3
Lymphoma
3
Lung Neoplasms
3
Gallbladder Neoplasms
3
Endometrial Neoplasms
3
Carcinoma
3
Bile Duct Neoplasms
3
Advanced Solid Tumors
3
Triple Negative Breast Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Spinocerebellar Degenerations
2
Recurrence
2
Interventions
Rituximab
13
Cyclophosphamide
9
Magnetic Resonance Spectroscopy
7
Lenalidomide
7
venetoclax
6
obinutuzumab
5
ibrutinib
5
Specimen Handling
5
fludarabine phosphate
4
fludarabine
4
Whole-Body Irradiation
4
Prednisone
4
CT-P10
4
Biopsy
4
zanubrutinib
3
orelabrutinib
3
Vincristine
3
Mycophenolic Acid
3
Cyclosporine
3
polatuzumab vedotin
2
pirtobrutinib
2
Tacrolimus
2
Peripheral Blood Stem Cell Transplantation
2
Doxorubicin
2
Busulfan
2
Bendamustine Hydrochloride
2
voruciclib
1
treosulfan
1
tafasitamab
1
prednylidene
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lymphoma, B-Cell, Marginal Zone
×
Oxaliplatin
×
90 days
×
Clear all
NCT04542824
2026-06-02
EPCOREâ„¢ NHL-3
Genmab
Phase 1/2
Active not recruiting
78 enrolled